Article

CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study

Wondmagegn Tamiru Tadesse 1, Eulambius Mathias Mlugu 2,3, Workineh Shibeshi 1*, Wondwossen Amogne Degu 4, Ephrem Engidawork 1* and Eleni Aklillu 2,4*

1 Department of Pharmacology and Clinical Pharmacology, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia; wondmagegn.tamiru@aau.edu.et (W.T.T.); workineh.shibeshi@aau.edu.et (W.S.); ephrem.engidawork@aau.edu.et (E.E.)
2 Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital-Huddinge, 14186 Stockholm, Sweden; mlugusonlove@gmail.com
3 Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam P.O. Box 65014, Tanzania
4 Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia; wonamogne@yahoo.com
* Correspondence: eleni.aklillu@ki.se

Abstract: Long-term antiretroviral treatment (cART) increases the risk of glucose metabolism disorders (GMDs). Genetic variation in drug-metabolizing enzymes and transporters may influence susceptibility to cART-associated GMDs. We conducted a case-control study to investigate the association of pharmacogenetic variations with cART-induced GMDs. A total of 240 HIV patients on long-term efavirenz-based cART (75 GMD cases and 165 controls without GMDs) were genotyped for CYP3A4*1B, CYP3A5 (*3,*6), CYP2B6*6, UGT2B7*2, ABCB1 (c.3435C>T, c.4036A>G), and SLCO1B1 (*1b, *5). GMD cases were defined as the presence of impaired fasting glucose, insulin resistance, or diabetes mellitus (DM). Case-control genotype/haplotype association and logistic regression analysis were performed by adjusting for age, sex, and BMI. The major CYP3A haplotypes were CYP3A5*3 (53.8%), CYP3A4*1B (17.3%), combinations of CYP3A4*1B, and CYP3A5*6 (10.9%), and CYP3A wild type (7%). CYP3A5*6 allele (p = 0.005) and CYP3A5*6 genotype (p = 0.01) were significantly associated with GMD cases. Multivariate analysis indicated CYP3A haplotype as a significant predictor of GMD (p = 0.02) and IFG (p = 0.004). CYP2B6*6 significantly predicted DM (p = 0.03). CYP3A haplotype and CYP2B6*6 genotype are independent significant predictors of GMD and DM, respectively, among HIV patients on long-term EFV-based cART.

Keywords: antiretroviral therapy; efavirenz; glucose metabolic disorder; HIV; pharmacogenetic variation; CYP3A5; CYP2B6; genotype; Ethiopia

1. Introduction

The introduction of combination antiretroviral therapy (cART) significantly improved survival and health-related quality of life among people living with HIV (PLWH) [1,2]. Efavirenz (EFV)-based cART is among the first-line antiretroviral regimen to treat HIV recommended by the World Health Organization [1]. Before its takeover by dolutegravir, EFV served as the backbone of the preferred first-line antiretroviral regimen due to its clinical, operational, and programmatic benefits.

Various observational and clinical trial studies link EFV use with a range of treatment-associated adverse events manifested depending on the duration of therapy. While liver enzyme abnormalities [3–6] and neuropsychological manifestations [7,8] can occur during early treatment, HIV patients on long-term antiretroviral therapy are at an increased risk of developing metabolic derangements, including lipid dystrophy and glucose metabolism...
disorders (GMDs) [9–11]. Indeed, a higher risk of GMDs among HIV patients on EFV-based cART than on atazanavir/ritonavir-based cART has been reported recently [11].

Several factors determine individuals’ susceptibility to cART-associated adverse events [12,13], including comorbidities and concomitant medications, host-genetic factors, and population variation [14–16]. Genetic variations in genes coding for drug-metabolizing enzymes and transporter proteins can alter plasma concentration and drug exposure, ultimately affecting treatment outcomes. Efavirenz is metabolized by genetically polymorphic CYP enzymes expressed in the liver. It is primarily metabolized to hydroxylated metabolites by CYP2B6, though other CYPs, including CYP3A4/5, CYP1A2, and CYP2A6, also play a minor role [17]. Genetic variations in drug-metabolizing enzymes affect EFV plasma exposure [15,18,19], thereby altering treatment outcomes [4,8].

Pharmacogenetic variation in relevant EFV metabolizing enzymes and transporter proteins may be linked with metabolic derangements and result in clinical conditions, including treatment-associated adverse events. Indeed, the association of CYP2B6 defective variant allele and higher plasma efavirenz exposure with liver enzyme abnormalities [3–5,20] and neuropsychological manifestations is reported [7,8,20].

Accumulating evidence in the literature indicates that long-term efavirenz-based cARTs are associated with GMDs in PLWH [11,21,22]. The importance of pharmacogenetic variations for cART-induced liver and CNS toxicities is well explored. Inter-individual variations in drug metabolic capacity due to genetic variations of drug-metabolizing enzyme and transporter genes may play a role in the predisposition to GMDs (insulin resistance (IR) or impaired fasting glycemia (IFG)) in antiretroviral therapy (ART).

No studies have been conducted to assess the association of GMDs with genetic variations in enzymes and transporter proteins involved in the disposition of EFV. Pharmacogenetic association studies are important to identify genetic biomarkers that predict specific ADRs associated with ARVs. Identifying risk factors of EFV-based cART-associated GMD is imperative in Africa, where HIV remains a significant public health problem. Here, we assessed the association of common functional variant alleles in relevant drug-metabolizing enzymes (CYP3A4, CYP3A5, CYP2B6, and UGT2B7) and transporters (ABCB1 and SLCO1B1) with cART-associated GMDs.

2. Materials and Methods
2.1. Study Setting Design and Participants

The study setting was the HIV clinic of Tikur Anbessa Specialized Hospital (TASH), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. TASH, being the largest tertiary level teaching and referral hospital in Ethiopia, serves about 500,000 patients each year through its various specialized clinical services. The hospital receives referred patients from different corners of the country and the city, providing an opportunity to recruit study participants representing a heterogeneous mix of different ethnic populations and socioeconomic statuses of the country. The HIV clinic at TASH coordinates various activities encompassing HIV/AIDS prevention, patient care, and ART services for patients through scheduled follow-ups.

The study design was a case-control genotype association study, and the study population is described in our previous cross-sectional study [11]. In brief, a total of 240 participants on long-term EFV-based ART regimens with complete genotyping and GMD data participated in this study. The inclusion and exclusion criteria were stated in detail in our previous publication [11]. In brief, PLWH on EFV-based cART at least for one year with age ≥ 18 years were included, while PLWH diagnosed with DM, pregnancy, cancer, renal disease, liver disease, uncontrolled hypertension, or heart failure were excluded from this study. Additionally, patients on concomitant treatment with antipsychotics, anti-cancer agents, anti-TB, corticosteroids, hormonal agents, and antidiabetic agents were excluded.
Whole blood was collected after overnight fasting (8 to 12 h). Serum fasting blood glucose (FBG), insulin, and lipid profiles were determined. Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was calculated by using the following equation [23].

\[
\text{HOMA-IR} = \frac{\text{Fasting insulin} (\mu U/mL) \times \text{Fasting glucose} (\text{mmol/L})}{22.5}
\]

2.2. GMD Case Definitions

The following operational definitions were used [11].

1. DM was defined as a fasting glucose level of 126 mg/dL or higher.
2. IFG was defined as a fasting glucose level between 110 and 125 mg/dL.
3. IR was diagnosed by either a homeostasis model assessment insulin resistance (HOMA-IR) value of ≥3.8, Fasting plasma insulin of ≥20 µU/mL, or fasting glucose/insulin ratio of ≥4.5.
4. GMDs were defined as the presence of IFG, IR, or DM.

Controls were those individuals with normal fasting serum glucose, HOMA-IR, or serum insulin level based on the above-stated cut-off values as stated by Tadesse et al. [11]. The cases were those individuals with at least one diagnosis with insulin resistance, impaired fasting glycaemia, or diabetes mellitus. The case and control groups were matched to each other in terms of age, duration since cART start, duration on current cART, weight, waist circumference, and BMI. Out of 240 participants, 75 cases and 165 controls were recruited in this study.

2.3. Genotyping

Whole blood samples were collected for genotype analysis in EDTA coated vacutainer tube and inverted 8–10 times for thorough mixing of EDTA. The samples were then transferred to cryotubes and stored at −80 °C until genotyping analysis. Genomic DNA was isolated from whole-blood samples using QIAamp DNA MidiKit (QIAGEN GmbH, Hilden, Germany) according to the manufacturer’s instructions. Purity and quantity of DNA were assessed using NanoDrop 2000 (Thermo Scientific, Saveen Werner, Sweden). Allelic discrimination assay was performed using TaqMan drug metabolism genotyping assay (Applied Biosystems, Foster City, CA, USA).

Functional variant alleles in enzymes and transport proteins relevant for disposition of EFV based cART were selected for genotyping [15,17]. The variant alleles were CYP3A4*1B, CYP3A5*3, CYP3A5*6, CYP2B6*6, UGT2B7*2, ABCB1 (c.3435C>T and c.4036A>G), and SLCO1B1 (*1B, *5). Genotyping was performed using TaqMan® allele-specific PCR (Applied Biosystems Genotyping Assays) with the following ID numbers for respective SNPs: C__7586657_20 for ABCB1c.3435C>T, C__71171730_20 for ABCB1c.4036A>G, C__7817765_60 for CYP2B6 c.516G>T (CYP2B6*6), C__30720663_20 for UGT2B7 – 327G>A (UGT2B7*2b, *2c, *2d, *2f), C__9440184_20 for UGT2B15*4, C__26201809_30 for CYP3A5*3 (6986A>G), C__30203950_10 for CYP3A5*6 (14690G>A), C__1837671_50 for CYP3A4*1B, C__1901697_20 for SLCO1B1*1B, C__30633906_10 for SLCO1B1*5. The 7500 Real-Time PCR system (Applied Biosystems) was used for genotyping. The final volume was 10 µL for each reaction, consisting of 9 µL of TaqMan Universal PCR Master Mix® (Applied Biosystems, Waltham, MA, USA), DNA/RNA free water, TaqMan 20× drug-metabolism genotyping assay mix (Applied Biosystems), and 1 µL of genomic DNA. The PCR conditions were as follows: an initial step at 60 °C for 30 s, hold-stage at 95 °C for 10 min and PCR stage for 40 cycles step 1 with 95 °C for 15 and step 2 with 60 °C for 1 min and after read-stage with 60 °C for 30 s.

2.4. Statistical Analysis

Hardy–Weinberg equilibrium was assessed by chi-square test for each SNP to determine any differences between observed and expected genotype frequencies. Statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version 26.
Haploview version 4.2 was employed to determine the association and case-control analysis of genotypes and haplotypes. The association of GMDs with genetic variants was determined through logistic regression analysis. Univariate followed by a multivariate logistic regression model was used to determine the association of GMD with genotype variants after adjusting for factors such as age, sex, and BMI among the groups. Genotypes with a univariate analysis of \( p < 0.2 \) were entered in the multivariate analysis. A stepwise conditional-backward analysis was employed when three or more genotypes meet the stated entry criteria for multivariate analysis. When only one or two genotypes meet the entry criteria, a direct enter method (without a stepwise) was used in the multivariate analysis. \( p \)-values of <0.05 were considered statistically significant. The regression coefficient (\( \beta \)), crude odds ratio (COR), and adjusted odds ratio (AOR) were recorded from univariate and multivariate logistic regression.

2.5. Ethical Consideration

Ethical clearance was obtained from the Institutional Review Board of College of Health Sciences, Addis Ababa University (Protocol No. 019/19/SoP) and National Ethical Review Committee, Ministry of Science and Higher Education of Ethiopia (Ref. No. MoSHE/RD14.1/9324/20). Written informed consent was obtained from each study participant after fully explaining the purpose and nature of all procedures used.

3. Results

3.1. Characteristics of Study Participants

A comparison of sociodemographic, clinical, and biochemical parameters between HIV patients who developed GMD (cases) versus those who did not develop GMD (controls) is presented in Table 1. The highest mean age (46.6 ± 1.3 years) was recorded in the case group. Unlike the case group, the distribution of males (21.7%) and females (78.3%) was disproportional among the control group. The other characteristics, such as weight, BMI, and duration on cART, did not show a significant difference between the case and the control groups (Table 1). Comparative clinical laboratory data for lipid measurements, fasting serum glucose, fasting serum insulin, and HOMA-IR values are shown in Table 1. A significant mean difference \( (p < 0.001) \) was observed in the biochemical markers of GMD between the control and the case groups (Table 1).

Table 1. Sociodemographic and biochemical parameters among HIV patients with glucose metabolic disorders (cases) versus without (controls).

| Variables                              | GMD Cases | Control | \( p \) |
|----------------------------------------|-----------|---------|--------|
| Sample (n) (case–control ratio)        | 75        | 165     | (1:2.2)|
| Gender n (%)                           | Male      | 40 (52.7)| 35 (21.7)| <0.001|
|                                         | Female    | 35 (47.3)| 130 (78.3)| |
| Age (years)                            | 46.6 ± 1.3| 43.8 ± 0.8| 0.06 |
| Duration since HIV confirmed date (month) | 141.6 ± 5.9| 130.5 ± 3.7| 0.10 |
| Cumulative time on cART (month)        | 129.2 ± 5.3| 120.9 ± 3.4| 0.19 |
| Time on current cART regimen type (month) | 95.3 ± 5.2| 92.1 ± 3.1| 0.59 |
| Cumulative time on EFV-based 1st-line (month) | 104.3 ± 5.0| 100.2 ± 3.3| 0.49 |
| Time on prior cART regimen types (month) | 32.2 ± 4.4| 36.2 ± 8.0| 0.74 |
Table 1. Cont.

| Variables                                      | GMD Cases          | Control         | p     |
|------------------------------------------------|--------------------|-----------------|-------|
| Time on NVP-based 1st-line (Prior to EFV) (month) | 24.8 ± 4.0         | 20.8 ± 3.0      | 0.43  |
| Weight (Kg)                                    | 64.5 ± 1.4         | 62.7 ± 1.1      | 0.34  |
| Waist circumference (cm)                       | 34.8 ± 0.6         | 34.2 ± 0.4      | 0.37  |
| BMI (Kg/m²)                                    | 24.1 ± 0.5         | 24.2 ± 0.4      | 0.86  |
| Total cholesterol (mg/dL)                      | 205.4 ± 5.1        | 209.5 ± 14.2    | 0.85  |
| Triglyceride (mg/dL)                           | 185.0 ± 11.8       | 136.8 ± 4.3     | <0.001|
| HDL-C (mg/dL)                                  | 44.9 ± 2.3         | 46.8 ± 2.4      | 0.63  |
| LDL-C (mg/dL)                                  | 139.7 ± 18.5       | 133.4 ± 10.0    | 0.75  |

Biochemical markers of GMD

|                       | Fasting serum glucose (mg/dL) | Fasting serum insulin (µLU/mL) | HOMA-IR |
|-----------------------|-------------------------------|--------------------------------|---------|
| Biochemical markers   | 117.7 ± 4.9                   | 16.9 ± 2.3                     | 5.3 ± 1.0|
| of GMD                | 94.0 ± 0.6                    | 7.1 ± 0.3                      | 1.7 ± 0.1|

3.2. Genotype, Allele, and Haplotype Frequencies

Comparison of CYP3A4*1B, CYP3A5*3, CYP3A5*6, CYP2B6*6, UGT2B7*2, ABCB1 c.3435C>T, ABCB1c.4036A>G, SLCO1B1*1B, and SLCO1B1*5 genotype and allele frequencies between control and case groups are depicted in Table 2. All genotype frequencies were in accordance with Hardy–Weinberg equilibrium (HWE) (p > 0.05).

The variant allele frequency CYP3A5*6 was significantly higher among GMD cases than in the control groups (0.41 versus 0.24) (p = 0.005). The linkage disequilibrium (LD) analysis demonstrated a linkage among the three CYP3A valiant alleles, and the relatively stronger linkage was between CYP3A4*1B and CYP3A5*3 (Figure 1). The major CYP3A haplotype was CYP3A5*3 alone (53.8%), followed by CYP3A4*1B alone (17.3%) and then by CYP3A5*1B linkage with CYP3A5*6 (10.9%) (Table 3). Based on Haploview case-control analysis, the CYP3A5*6 allele was significantly associated with IFG, IR, and overall GMD, while the CYP2B6*6 allele was significantly associated with DM (not shown in tables).

Figure 1. Linkage disequilibrium (LD) plot of the studied genotype variants among Ethiopian PLWH on EFV-based cART. The values in the diagonal square boxes represent the respective observed D’ values of the pair-wise LD relationship. The red color gradient indicates higher LD values while the white represents lower LD values (D’ 1–0).
Table 2. Genotype and variant allele frequency distribution and association with glucose metabolism disorders (GMD) among PLWH (N = 351).

| Genotypes          | Variants | Control, n (%) | Case, n (%) | p     |
|--------------------|----------|----------------|-------------|-------|
| CYP 3A4*1B (−392A>G) | *1/*1    | 70 (42.4)      | 28 (37.5)   | 0.48  |
|                    | *1/*1B   | 79 (47.9)      | 36 (48.0)   |       |
|                    | *1B/*1B  | 16 (9.7)       | 11 (14.7)   |       |
| CYP3A5*3 c.6986A>G | *1/*1    | 16 (9.7)       | 10 (13.3)   | 0.63  |
|                    | *1/*3    | 82 (49.7)      | 38 (50.7)   |       |
|                    | *3/*3    | 67 (40.6)      | 27 (36.0)   |       |
| CYP3A5*6 c.14690G>A | *1/*1    | 126 (76.4)     | 44 (58.7)   | 0.01  |
|                    | *1/*6    | 36 (21.8)      | 29 (38.7)   |       |
|                    | *6/*6    | 3 (1.8)        | 2 (2.7)     |       |
| CYP2B6*6 c.516G>T  | *1/*1    | 81 (49.1)      | 30 (40.0)   | 0.42  |
|                    | *1/*6    | 70 (42.4)      | 38 (50.7)   |       |
|                    | *6/*6    | 14 (8.5)       | 7 (9.3)     |       |
| UGT2B7*2 (−372G>A) | GG       | 39 (23.6)      | 17 (22.7)   | 0.70  |
|                    | GA       | 86 (52.1)      | 36 (48.0)   |       |
|                    | AA       | 40 (24.2)      | 22 (29.3)   |       |
| ABCB1 c.3435C>T    | CC       | 93 (56.4)      | 45 (60.0)   | 0.65  |
|                    | CT       | 62 (37.6)      | 24 (32.0)   |       |
|                    | TT       | 10 (6.1)       | 6 (8.0)     |       |
| ABCB1 c.4036A>G    | AA       | 107 (64.8)     | 53 (70.7)   | 0.32  |
|                    | AG       | 55 (33.3)      | 19 (25.3)   |       |
|                    | GG       | 3 (1.8)        | 3 (4.0)     |       |
| SLCO1B1*1B c.388A>G| AA       | 22 (13.3)      | 8 (10.7)    | 0.84  |
|                    | AG       | 91 (55.2)      | 43 (57.3)   |       |
|                    | GG       | 52 (31.5)      | 24 (32.0)   |       |
| SLCO1B1*5 c.521T>C | TT       | 108 (65.5)     | 49 (65.3)   | 0.71  |
|                    | TC       | 49 (29.7)      | 24 (32.0)   |       |
|                    | CC       | 5 (4.8)        | 2 (2.7)     |       |

| Minor Variant Allele | Allele Frequency | p     |
|----------------------|-----------------|-------|
| CYP3A4*1B (−392A>G)  | *1B             | 0.58  | 0.06 |
|                      | *3              | 0.9   | 0.4  |
| CYP3A5*3 (c.6986A>G) | *1              | 0.24  | 0.005|
|                      | *6              | 0.51  | 0.19 |
| CYP2B6*6 (c.516G>T) | *1              | 0.26  | 0.87 |
|                      | *6              | 0.44  | 0.6  |
| UGT2B7*2 (−372G>A)  | A               | 0.35  | 0.38 |
|                      | T               | 0.35  | 0.56 |
| ABCB1 c.3435C>T     | G               | 0.35  | 0.99 |
| SLCO1B1*1B c.388A>G | G               | 0.35  | 0.99 |
| SLCO1B1*5 c.521T>C  | C               | 0.35  | 0.99 |

Table 3. GMD case-control analysis of CYP3A haplotype using Haploview among HIV patients on long-term EFV-based cART.

| CYP3A Haplotypes | CYP3A Allele Combinations | F (%) | p-Values |
|------------------|---------------------------|-------|----------|
|                  | GMD | IFG | IR | DM |
| AGG | wt | *3 | wt | 53.8 | 0.40 | 0.20 | 0.41 | 0.56 |
| GAG | *1B | wt | wt | 17.3 | 0.90 | 0.81 | 0.89 | 0.27 |
| GAA | *1B | wt | *6 | 10.9 | 0.04 | 0.008 | 0.04 | 0.35 |
| GGG | *1B | *3 | wt | 6.3 | 0.45 | 0.17 | 0.57 | 0.35 |
| AAG | wt | *3 | wt | 7.0 | 0.13 | 0.99 | 0.15 | 0.49 |
| AGA | wt | *3 | *6 | 3.4 | 0.34 | 0.32 | 0.60 | 0.99 |

F (%) represent haplotype frequency distribution; level of significance (p-values) are based on Haploview case-control analysis for CYP3A haplotypes; Wt—wildtype; GMD—glucose metabolism disorder; IFG—impaired fasting glycemia; IR—insulin resistance; DM—diabetes mellitus.
3.3. Genotype/Haplotype Association with GMD

Based on Haploview case-control analysis, $3A4^*1B + 3A5^*6$ haplotype combinations of CYP3A showed a significant association with GMD ($p = 0.04$) (Table 3). The multivariate analysis revealed that the $3A4^*1B + 3A5^*3 + 3A5^*6$ (*1B/3/6) haplotype combination of CYP3A was found to be an independent predictor of GMD when the wildtype and the *1B haplotype carriers used as a reference group (overall $p = 0.02$) (Table 4). Among carriers of CYP3A4*1B + 3A5*3 + 3A5*6 haplotype, the odds of experiencing GMD were about 2.2-fold higher (AOR = 2.2; 95% CI 1.0–4.8, $p = 0.04$) than carriers of the wildtype (with two functional alleles) or CYP3A5*3 alone haplotype combinations.

Table 4. GMD regression analysis of drug-metabolizing and transporter genotypes with glucose metabolism disorders (GMD) and impaired fasting glycemia (IFG) among HIV patients on long-term EFV-based cART ($n = 240$).

| Genotype | GMD among EFV-Based cART | IFG among EFV-Based cART |
|----------|--------------------------|--------------------------|
|          | COR (95% CI) p | AOR (95% CI) p | COR (95% CI) p | AOR (95% CI) p |
| CYP3A haplotypes | | | | |
| (3A4*1B/3A5*3/3A5*6) | | | | |
| *1/*1/*1 or *1B/*1/*1 | 1 | 0.02 | 1 | 0.02 | 1 | 0.004 | 1 | 0.004 |
| *1/*3/*3 or *1B/*3/*1 | −0.4 | 0.7 (0.2, 2.4) | 0.56 | −0.4 | 0.6 (0.2, 2.3) | 0.5 | −0.6 | 0.6 (0.1, 2.8) | 0.47 | −0.6 | 0.6 (0.1, 2.8) | 0.47 |
| *1B/*3/*6 or *1/*3/*6 (any 3A5*6) | 0.5 | 1.6 (0.4, 5.7) | 0.49 | 0.4 | 1.5 (0.4, 5.6) | 0.52 | 0.7 | 1.9 (0.4, 9.7) | 0.42 | 0.7 | 1.9 (0.4, 9.7) | 0.42 |
| CYP2B6*6 (c.516G>T) | | | | |
| *1/*1 | 1 | 1 | | | |
| *1/*6 or *6/*6 | 0.4 | 1.4 (0.8, 2.5) | 0.19 | 0.4 | 1.5 (0.9, 2.7) | 0.13 | 0.01 | 1.0 (0.5, 2.0) | 0.97 |
| UGT2B7*2b (−327G>A) | | | | |
| GG | 1 | 1 | | | |
| GA or AA | 0.1 | 1.1 (0.6, 2.0) | 0.87 | | | |
| ABCB1 c.3435C>T | | | | |
| CC | 1 | 1 | | | |
| CT or TT | −0.2 | 0.9 (0.5, 1.5) | 0.6 | 0.2 | 1.2 (0.6, 2.4) | 0.65 |
| ABCB1 c.4036A>G | | | | |
| AA | 1 | 1 | | | |
| AG or GG | −0.3 | 0.8 (0.4, 1.4) | 0.38 | −0.05 | 1.0 (0.5, 2.2) | 0.9 |
| SLCO1B1*1B (c.388A>G) | | | | |
| AA | 1 | 1 | | | |
| AG or GG | 0.3 | 1.3 (0.5, 3.0) | 0.56 | −0.1 | 0.9 (0.3, 2.5) | 0.84 |
| SLCO1B1*5 (c.521T>C) | | | | |
| TT | 1 | 1 | | | |
| TC or CC | 0.01 | 1.0 (0.6, 1.8) | 0.99 | −0.1 | 0.9 (0.4, 1.9) | 0.77 |

COR—crude odds ratios; AOR—adjusted odds ratio.

3.4. Genotype/Haplotype Association with IFG

As depicted in Table 3, the Haploview case-control analysis revealed that $3A4^*1B + 3A5^*6$ haplotype combinations of CYP3A demonstrated a significant association with IFG ($p < 0.01$), whereas the multivariate analysis (Table 4) showed that the overall CYP3A haplotypes were significantly associated with IFG ($p = 0.004$). In alternative multivariate analysis, the odds of developing IFG was 2.8-times higher among $3A4^*1B + 3A5^*3 + 3A5^*6$ haplotype carriers compared to the wildtype or CYP3A5*3-alone haplotype carriers (AOR = 2.8, 95% CI 1.1–7.1, $p = 0.04$).
3.5. Association with Insulin Resistance

Based on Haploview case-control analysis, carriers of CYP3A4*1B + 3A5*6 haplotype combination of CYP3A locus showed a significant association with the incidence of IR ($p = 0.04$) (Table 3). CYP3A haplotypes showed marginal association compared to the wildtype and the *1B haplotype carriers ($p = 0.06$) (Table 5). In alternative multivariate analysis (not shown in tables), 3A4*1B + 3A5*3 + 3A5*6 haplotype combination predicted the incidence of IR. The odds of IR risk were 2.6 for 3A4*1B + 3A5*3 + 3A5*6 haplotype carriers ($AOR = 2.6; 95\% CI 1.0–6.8, p = 0.05$) compared to the wildtype or CYP3A5*3-alone haplotype combinations. In addition, the T allele of ABCB1 c.3435T showed a significant 60% protection of IR ($AOR = 0.4, 95\% CI 0.2–0.9, p = 0.04$) relative to the wildtype ABCB1 c.3435 C allele (Table 5).

Table 5. Logistic regression analysis of drug-metabolizing and transporter genotypes with insulin resistance (IR) and diabetes mellitus (DM) among HIV patients on long-term EFV-based cART ($n = 240$).

| Genotype                          | IR among EFV-Based cART | DM among EFV-Based cART |
|----------------------------------|-------------------------|-------------------------|
|                                  | COR (95% CI) p | AOR (95% CI) p | COR (95% CI) p | AOR (95% CI) p |
| CYP3A haplotypes (3A4*1B/3A5*3/3A5*6) |             |               |               |               |
| *1/*1/*1 or *1B/*1/*1             | 1.0 (0.6, 1.5) | 0.38 (0.1, 0.9) | 1.0 (0.8, 1.2) | 0.38 (0.1, 0.9) |
| *1/*3/*1 or *1B/*3/*1             | 0.4 (0.2, 0.7) | 0.60 (0.4, 0.8) | 0.4 (0.2, 0.8) | 0.60 (0.4, 0.8) |
| *1B,*6/*3 or *1B/*3/*6 (any *6)   | 0.6 (0.4, 0.8) | 0.60 (0.4, 0.8) | 0.6 (0.4, 0.8) | 0.60 (0.4, 0.8) |
| CYP2B6*6 (c.516G>T)             |               |               |               |               |
| *1/*1 or *6/*6                   | 0.6 (0.5, 0.8) | 0.60 (0.4, 0.8) | 0.6 (0.5, 0.8) | 0.60 (0.4, 0.8) |
| UGT2B7*2b (~327G>A)             |               |               |               |               |
| GA or AA                        | 0.8 (0.5, 1.3) | 0.5 (0.3, 0.7) | 0.8 (0.5, 1.3) | 0.5 (0.3, 0.7) |
| ABCB1 c.3435C>T                 |               |               |               |               |
| CC or TT                        | 0.5 (0.2, 1.0) | 0.12 (0.0, 0.2) | 0.5 (0.2, 1.0) | 0.12 (0.0, 0.2) |
| ABCB1 c.4036A>G                 |               |               |               |               |
| AA or GG                        | 0.6 (0.5, 1.4) | 0.25 (0.1, 0.6) | 0.6 (0.5, 1.4) | 0.25 (0.1, 0.6) |
| SLCO1B1*1B (c.388A>G)           |               |               |               |               |
| AA or GG                        | 0.6 (0.5, 1.4) | 0.25 (0.1, 0.6) | 0.6 (0.5, 1.4) | 0.25 (0.1, 0.6) |
| SLCO1B1*5 (c.521T>C)            |               |               |               |               |
| TT or CC                        | 0.5 (0.3, 0.8) | 0.1 (0.0, 0.3) | 0.5 (0.3, 0.8) | 0.1 (0.0, 0.3) |

COR—crude odds ratios; AOR—adjusted odds ratio.

3.6. Association with DM

As depicted in Table 5, CYP2B6*6 c.516G>T genotype significantly predicted the incidence of DM among study participants on EFV-based cART. Based on multivariate regression analysis, carriers of CYP2B6*6 alleles were at a significantly higher risk of DM by 4-fold than the wildtype carriers ($AOR = 0.4; 95\% CI 1.1–14.5; p = 0.03$). No significant association of DM with the other genotypes was observed.
4. Discussion

Long-term ART is associated with several metabolic adverse effects, including GMDs (i.e., IR, IFG, or Type 2 diabetes). Long-term efavirenz-based cART-associated metabolic derangements, including GMD, are likely due to mitochondrial toxicity [9]. Growing evidence implicates the role of efavirenz in energy metabolism, mitochondrial function, and other cellular processes involved in oxidative stress [24,25]. Efavirenz exposure lowers glucose uptake and alters bioenergetic cell profiles in human cell lines through inhibition of SLC2A1, which mediates cellular glucose uptake [26]. This result in reduced glucose metabolism in immune cells, suppressing immune cell activation. The primary metabolite of efavirenz, 8-Hydroxy-efavirenz, stimulates the glycolytic flux in cultured rat astrocytes [27]. Association of high plasma efavirenz concentrations with high plasma fasting lipid concentrations and glucose concentrations in South African HIV patients treated with efavirenz-based ART is reported [28]. In our previous study, a higher prevalence of GMDs (27.6%) was reported among HIV patients on a long-term EFV-based regimen [11].

Altered efavirenz metabolism and disposition due to pharmacogenetic variation may influence susceptibility to treatment-induced glucose metabolic disorder. So far, no literature investigated the association of GMDs with functional variant alleles in genes relevant for EFV disposition among PLWH on long-term treatment. Therefore, in this case-control study, we investigated the association of genotype/haplotype variants with the incidence of GMDs among Ethiopian PLWH on EFV-based cARTs. The main finding of this study includes (1) CYP3A haplotype, particularly CYP3A4*1B + 3A5*3 + 3A5*6 allele combinations, which were a significant predictor of IR, IFG, and overall GMD, and (2) CYP2B6*6 is significantly associated with the risk of developing DM in EFV-based cART. To our knowledge, this is the first study to explore the importance of pharmacogenetic variation for susceptibility to antiretroviral treatment-induced GMD.

There was no statistically different mean in the age, duration of time since cART start, period on the current cART type, weight, waist circumference, and BMI between the case and the control groups, implying a matching between the case and the control groups in the study. We also showed that cases had significantly elevated HOMA-IR, FSG, FSI, and TG levels than controls, indicating the presence of GMDs. The overall observed genotype and allele frequency proportions were similar to the findings of previous studies from Ethiopia [29,30].

Interestingly, the distribution of CYP3A5*6 allele and genotype frequencies between cases and controls were significantly different, being higher in cases than in controls (Table 2). CYP3A haplotype combination containing 3A5*6 significantly predicted the incidence of IR, IFG, and overall GMD than the wildtype or CYP3A5*3 alone carriers (Table 3). case-control analysis showed the association of CYP3A4*1B and CYP3A5 variants with the incidence of GMD, particularly when 3A4*1B and 3A5*6 variants co-occur. Though patients on antiretroviral therapy were not stated to be included, a Japanese case-control study indicated that CYP3A4 (I3989A>G) polymorphism is associated with the prevalence of type 2 diabetes mellitus [31]. Additionally, another study reported the association of CYP3A4*18B with the incidence of tacrolimus-induced new-onset diabetes while reporting no association of CYP3A5 variants with new-onset type 2 diabetes in renal transplant recipients [32], but these studies were on study participants with different disease conditions and types of treatment than our study participants that limited direct comparison.

The effect of the CYP3A4*1B genotype on enzyme activity is not fully understood, and data are inconclusive. As a proximal promoter variant, however, the CYP3A4*1B polymorphisms may influence protein expression more than the catalytic activity. While studies indicated reduced enzyme activity [33], there are also reports of higher expression and enzyme activities among carriers of *1B [34]. Nevertheless, CYP3A4*1B appears to have no or very limited functional impact on CYP3A4 enzyme activity, and variation in the overall CYP3A enzyme activity is mainly influenced by its linkage disequilibrium with CYP3A5 variant alleles common in the black African population [35–37]. CYP3A enzyme activity and genetic variation display wide between-population variation even within black
Africans [35]. The major CYP3A haplotype in Tanzanians is CYP3A4*1B alone (34.2%), followed by its linkage with CYP3A5*6 (17.6%) and CYP3A5*3 (13.3%) [36]. CYP3A5*7 is absent in Ethiopians. In our study, we found the major CYP3A haplotype among Ethiopians being CYP3A4*3 alone (53.8%) and CYP3A4*1B alone (17.3%), followed by CYP3A4*1B linkage with CYP3A5*6 (10.9%) or CYP3A5*3 (6.3%). In the case of CYP3A5*3, as it has reduced activity, it may function better, unlike the null-functioning CYP3A5*6 variant in metabolizing activity. Yet, the CYP3A4*1B + CYP3A5*6 haplotype carriers have reduced active enzymes than carriers of CYP3A5*3 allele or wildtype haplotype.

The higher association of GMD with the 3A4*1B + 3A5*6 haplotype in our study may arise due to the impact of CYP3A5*6 null-functional status. Supporting this assertion, the allele-based case-control analysis (Haploview) consistently showed the association of CYP3A5*6 with GMDs. In general, the implication of the association of GMD with these variants could be due to a defective enzyme function which might result in higher plasma drug exposure linked with the risk of GMDs. Yet, the exact molecular mechanism that links CYP3A variants to GMD remains to be explored.

Notably, the CYP2B6*6 genotype significantly predicted the incidence of DM. Similarly, the case-control analysis showed that the CYP2B6*6 allele frequency was significantly higher in the GMD case group than in the control group implying the link between a defective enzyme function with the risk of DM in long-term EFV-based cART. To our knowledge, this is the first finding that showed a statistically significant association of the CYP2B6 variant allele with the incidence of DM among long-term EFV-based regimens. The CYP2B6*6 genotype determines interindividual variability of plasma efavirenz exposure. In our study, CYP2B6*6 (c.516G>T) carriers had a four-fold higher risk of DM as compared to the wildtype carriers. Different from our findings, a previous study did not observe a significant association of CYP2B6*6 with fasting glucose and 2-hour glucose concentration among patients on EFV-based regimens. The authors explained that the small sample size with the genotype data might have limited their study to detect statistically significant genetic associations [28].

In addition, ABCB1 c.3435C>T was associated with IR, where the T allele showed a more protective effect than the wildtype. A Turkish case-control study, despite methodological differences from our study, reported that the homozygous mutant of ABCB1 c.3435C>T is associated with higher BMI among the control group than in Type 2 DM cases [38], implying a protective role among the case group. Similarly, our study showed a trend that the T allele frequency is slightly higher among control groups than in the cases, although not statistically significant. However, the multivariate analysis revealed that the mutant variants protectively predicted IR. The explanation for this might be that the ABCB1, which encodes the efflux transporter P-glycoprotein is involved in the transport of substrates such as sugars, lipids, amino acids, and steroids, apart from their pharmacokinetic role. Functionally, studies suggest that variants with the T allele and the homozygous ABCB1 c.3435C>T mutant are linked with reduced expression and functioning of efflux transporters [39]. Thus, SNPs in these genes might alter substrate-related risk factors preventing the occurrence of metabolic conditions such as obesity, one of the predominant risk factors of IR and GMDs, resulting from altered hormonal or physiological biomolecules [40].

In our study, we employed a candidate gene association approach considering variant alleles that may affect the disposition of an EFV-based ART regimen. To our knowledge, for the first time, our study generated evidence of the association between pharmacogenetic variations in drug-metabolizing enzymes and drug transporters relevant for the disposition of antiretrovirals with metabolic disorders such as IR, IFG, and DM among PLWH. The inclusion of insulin and IR parameters as GMD would provide a cumulative prediction of such incidences among PLWH on long-term cART. One of the limitations of our study is that, although in at least 1–4 cases, the control ratio was maintained in most gene variants, the number of participants in the case group was relatively smaller than in the control groups. Our study also focused only on related pharmacokinetic genes and did not consider other SNPs of genes directly involved in carbohydrate metabolism and insulin release.
Therefore, we recommend confirmatory studies on a larger sample size with more extended and repeated follow-ups for future studies.

5. Conclusions

Our findings suggested that CYP3A, CYP2B6, and ABCB1 genotypes predicted treatment-associated GMDs to a varying degree among HIV patients on long-term EFV-based combination antiretroviral therapies. Mainly, the defective functional CYP3A5*6 allele and its haplotype combination (3A4*1B/3A5*3/*3A5*6) were independent predictors of the overall GMDs, IR, and IFG. Intriguingly, the CYP2B6*6 genotype significantly predicted the occurrence of DM (increased risk) on long-term EFV-based cART. Further studies with a large sample size are needed to confirm our findings among PLWH on cART.

Author Contributions: Conceptualization, W.T.T., W.A.D., E.E. and E.A.; methodology, W.T.T., E.M.M., W.A.D., E.E. and E.A.; software, W.T.T., E.M.M. and E.A.; validation, W.T.T., W.A.D., E.E. and E.A.; formal analysis, W.T.T., E.M.M. and E.A.; investigation, W.T.T., E.M.M., W.S., W.A.D., E.E. and E.A.; resources, W.T.T., W.S., W.A.D., E.E. and E.A.; data curation, W.T.T., E.M.M. and E.A.; writing—original draft preparation, W.T.T.; writing—review and editing, W.T.T., E.M.M., W.S., W.A.D., E.E. and E.A.; visualization, W.T.T., E.M.M., E.E. and E.A.; supervision, W.A.D., E.E. and E.A.; project administration, W.T.T., W.A.D. and E.A.; funding acquisition, W.S., E.E. and E.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Swedish Research Council (Vetenskapsrådet, Grant number: 2015-03295); the European and Developing Countries Clinical Trials Partnership (EDCTP) 2 program supported by the European Union (Grant number CSA2016S-1618), and Swedish International Development Cooperation Agency grant for Addis Ababa University (GPO/275/12/20). The funder had no role in the study design, data collection, analysis, decision to publish, or preparation of this manuscript.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of College of Health Sciences, Addis Ababa University (Protocol No. 019/19/SoP), and National Ethical Review Committee, Ministry of Science and Higher Education of Ethiopia (Ref. No. MoSHE/RD14.1/9324/20).

Informed Consent Statement: Informed consent was obtained from all study participants involved in the study.

Data Availability Statement: All data presented in this study are contained within the manuscript.

Acknowledgments: We thank the study participants and staff members of ART Clinic of Tikur Anbessa Specialized Hospital (TASH) for their support during the study period.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2nd ed.; World Health Organization: Geneva, Switzerland, 2016; ISBN 978-92-4-154968-4.

2. Desta, A.; Biru, T.T.; Kefale, A.T. Health Related Quality of Life of People Receiving Highly Active Antiretroviral Therapy in Southwest Ethiopia. PloS ONE 2020, 15, e0237013. [CrossRef]

3. Yimer, G.; Ueda, N.; Habtewold, A.; Amogne, W.; Suda, A.; Riedel, K.-D.; Burhenne, J.; Aderaye, G.; Lindquist, L.; Makonnen, E.; et al. Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PloS ONE 2011, 6, e27810. [CrossRef]

4. Yimer, G.; Amogne, W.; Habtewold, A.; Makonnen, E.; Ueda, N.; Suda, A.; Worku, A.; Haefeli, W.E.; Burhenne, J.; Aderaye, G.; et al. High Plasma Efavirenz Level and CYP2B6*6 Are Associated with Efavirenz-Based HAART-Induced Liver Injury in the Treatment of Naïve HIV Patients from Ethiopia: A Prospective Cohort Study. Pharm. J. 2012, 12, 499–506. [CrossRef] [PubMed]

5. Mugusi, S.; Ngaimisi, E.; Janabi, M.; Minzi, O.; Bakari, M.; Riedel, K.-D.; Burhenne, J.; Lindquist, L.; Mugusi, F.; Sandstrom, E.; et al. Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. PloS ONE 2012, 7, e40180. [CrossRef] [PubMed]

6. Tadesse, B.T.; Foster, B.A.; Kabela, A.; Ayalew, F.; Meskel, G.; Jerene, D.; Makonnen, E.; Aklillu, E. Hepatic and Renal Toxicity and Associated Factors among HIV-Infected Children on Antiretroviral Therapy: A Prospective Cohort Study. HIV Med. 2019, 20, 147–156. [CrossRef] [PubMed]
7. Mugusi, S.; Ngaimisi, E.; Janabi, M.; Mugusi, F.; Minzi, O.; Aris, E.; Bakari, M.; Bertilsson, L.; Burhenne, J.; Sandstrom, E.; et al. Neuropsychiatric Manifestations among HIV-1 Infected African Patients Receiving Efavirenz-Based CART with or without Tuberculosis Treatment Containing Rifampicin. *Eur. J. Clin. Pharm.* 2018, 74, 1405–1415. [CrossRef] [PubMed]

8. Mukonzo, J.K.; Okwera, A.; Nakasujja, N.; Luzzo, H.; Sebwufu, D.; Ogwal-Okeny, J.; Waako, P.; Gustafsson, L.L.; Akilu, E. Influence of Efavirenz Pharmacokinetics and Pharmacogenetics on Neuropsychological Disorders in Ugandan HIV-Positive Patients with or without Tuberculosis: A Prospective Cohort Study. *BMC Infect. Dis.* 2015, 13, 261. [CrossRef]

9. Lagathu, C.; Béreziat, V.; Gorwood, J.; Fellahi, S.; Bastard, J.-P.; Vigouroux, C.; Boccara, F.; Capeau, J. Metabolic Complications Affecting Adipose Tissue, Lipid and Glucose Metabolism Associated with HIV Antiretroviral Treatment. *Expert Opin. Drug Saf.* 2019, 18, 829–840. [CrossRef]

10. Tadesse, B.T.; Foster, B.A.; Chala, A.; Chaka, T.E.; Bizuayehu, T.; Ayalew, F.; Meskel, G.; Tadesse, S.; Jerene, D.; Makonnen, E.; et al. HIV and CART-Associated Dyslipidemia Among HIV-Infected Children. *J. Clin. Med.* 2019, 8, 430. [CrossRef]

11. Tadesse, W.T.; Adankie, B.T.; Shibeshi, W.; Amogne, W.; Akilu, E.; Engidawork, E. Prevalence and Predictors of Glucose Metabolism Disorders among People Living with HIV on Combination Antiretroviral Therapy. *PLoS ONE* 2022, 17, e0262604. [CrossRef]

12. Petros, Z.; Makonnen, E.; Akilu, E. Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation. *OMICS* 2017, 21, 123–131. [CrossRef] [PubMed]

13. Yimer, G.; Gry, M.; Amogne, W.; Makonnen, E.; Habtewold, A.; Petros, Z.; Aderaye, G.; Schuppe-Koistinen, I.; Lindquist, L.; Akilu, E. Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients. *PLoS ONE* 2014, 9, e94271. [CrossRef] [PubMed]

14. Mugusi, S.; Habtewold, A.; Ngaimisi, E.; Amogne, W.; Yimer, G.; Minzi, O.; Makonnen, E.; Sudfeld, C.; Burhenne, J.; Akilu, E. Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Saharan African Populations. *Front. Pharmacol.* 2020, 11, 26. [CrossRef] [PubMed]

15. Ngaimisi, E.; Habtewold, A.; Minzi, O.; Makonnen, E.; Mugusi, S.; Amogne, W.; Yimer, G.; Riedel, K.-D.; Janabi, M.; Aderaye, G.; et al. Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations. *PLoS ONE* 2013, 8, e67946. [CrossRef]

16. Petros, Z.; Kishikawa, J.; Makonnen, E.; Yimer, G.; Habtewold, A.; Akilu, E. HLA-B*57 Allele Is Associated with Concomitant Anti-Tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. *Front. Pharm.* 2017, 8, 90. [CrossRef]

17. McDonagh, E.M.; Lau, J.L.; Alvarelles, M.; Altman, R.B.; Klein, T.E. PharmGKB Summary: Efavirenz Pathway, Pharmacokinetics (PK). *Pharm. Genom.* 2015, 25, 363–376. [CrossRef]

18. Swart, M.; Ren, Y.; Smith, P.; Dandara, C. ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African Patients with or without Tuberculosis Treatment Containing Rifampicin. *PLoS ONE* 2014, 9, e94271. [CrossRef] [PubMed]

19. Mukonzo, J.K.; Röshammar, D.; Waako, P.; Andersson, M.; Fukasawa, T.; Milani, L.; Svensson, J.O.; Ogwal-Okeny, J.; Gustafsson, L.L.; Akilu, E. A Novel Polymorphism in ABCB1 Gene, CYP2B6*6 and Sex Predict Single-Dose Efavirenz Population Pharmacokinetics in Ugandans. *Br. J. Clin. Pharm.* 2009, 68, 690–699. [CrossRef]

20. Sánchez Martínez, A.; Cabrera Figueroa, S.; Cruz Guerrero, R.; Hurtado, L.P.; Hurlé, A.D.-G.; Carracedo Álvarez, Á. Impact of Pharmacogenetics on CNS Side Effects Related to Efavirenz. *Pharmacogenomics* 2013, 14, 1167–1178. [CrossRef]

21. Njoroge, A.; Augusto, O.; Page, S.T.; Kishikawa, J.; Makonnen, E.; Yimer, G.; Habtewold, A.; Akilu, E. HLA-B*57 Allele Is Associated with Concomitant Anti-Tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. *Front. Pharm.* 2017, 8, 90. [CrossRef]

22. Maganga, E.; Smart, L.R.; Kalluvya, S.; Kataraihya, J.B.; Saleh, A.M.; Obeid, L.; Downs, J.A.; Fitzgerald, D.W.; Peck, R.N. Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults. *PLoS ONE* 2015, 10, e0134410. [CrossRef] [PubMed]

23. Muniyappa, R.; Madan, R.; Varghese, R.T. Assessing Insulin Sensitivity and Resistance in Humans. In *Endotext*; Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhahariya, K., Dungan, K., Hershman, J.M., Hofland, J., Kalra, S., et al., Eds.; MDText.com, Inc.: South Dartmouth, MA, USA, 2000.

24. George, J.W.; Mattingly, J.E.; Roland, N.J.; Small, C.M.; Lambert, B.G.; Fox, H.S.; Stauch, K.L.; Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells. *Front. Immunol.* 2021, 12, 639378. [CrossRef] [PubMed]

25. Apostolova, N.; Gomez-Sucerquia, L.; Moran, A.; Alvarez, A.; Blas-Garcia, A.; Esplugues, J. Enhanced Oxidative Stress and Increased Mitochondrial Mass during Efavirenz-Induced Apoptosis in Human Hepatic Cells: Mitotoxic Effect of Efavirenz in Human Hepatic Cells. *Br. J. Pharmacol.* 2010, 160, 2069–2084. [CrossRef] [PubMed]

26. Heaton, B.J.; Jensen, R.L.; Line, J.; David, C.A.W.; Brain, D.E.; Chadwick, A.E.; Liptrott, N.J. Exposure of Human Immune Cells, to the Antiretrovirals Efavirenz and Lopinavir, Leads to Lower Glucose Uptake and Altered Bioenergetic Cell Profiles through Interactions with SLC2A1. *Biomed. Pharmacother.* 2022, 150, 112999. [CrossRef]

27. Brandmann, M.; Nehls, U.; Dringen, R. 8-Hydroxy-Efavirenz, the Primary Metabolite of the Antiretroviral Drug Efavirenz, Stimulates the Glycolytic Flux in Cultured Rat Astrocytes. *Neurochem. Res.* 2013, 38, 2524–2534. [CrossRef]

28. Sinxadi, P.Z.; McIlerton, H.M.; Dave, J.A.; Smith, P.J.; Levitt, N.S.; Haas, D.W.; Maatens, G. Plasma Efavirenz Concentrations Are Associated with Lipid and Glucose Concentrations. *Medicine* 2016, 95, e2385. [CrossRef]
29. Aklillu, E.; Zumla, A.; Habtewold, A.; Amogne, W.; Makonnen, E.; Yimer, G.; Burhenne, J.; Diczfalusy, U. Early or Deferred Initiation of Efavirenz during Rifampicin-Based TB Therapy Has No Significant Effect on CYP3A Induction in TB-HIV Infected Patients. *Br. J. Pharm.* 2021, 178, 3294–3308. [CrossRef]

30. Chala, A.; Tadesse, B.T.; Chaka, T.E.; Mukonzo, J.; Kitabi, E.N.; Tadesse, S.; Pohanka, A.; Makonnen, E.; Aklillu, E. Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. *J. Pers. Med.* 2021, 11, 1303. [CrossRef]

31. Yamada, Y.; Matsuo, H.; Watanabe, S.; Kato, K.; Yajima, K.; Hibino, T.; Yokoi, K.; Ichihara, S.; Metoki, N.; Yoshida, H.; et al. Association of a Polymorphism of CYP3A4 with Type 2 Diabetes Mellitus. *Int. J. Mol. Med.* 2007, 20, 703–707.

32. Shi, D.; Xie, T.; Deng, J.; Niu, P.; Wu, W. CYP3A4 and GCK Genetic Polymorphisms Are the Risk Factors of Tacrolimus-Induced New-Onset Diabetes after Transplantation in Renal Transplant Recipients. *Eur. J. Clin. Pharm.* 2018, 74, 723–729. [CrossRef]

33. Rodriguez-Antona, C.; Sayi, J.G.; Gustafsson, L.L.; Bertilsson, L.; Ingelman-Sundberg, M. Phenotype-Genotype Variability in the Human CYP3A Locus as Assessed by the Probe Drug Quinine and Analyses of Variant CYP3A4 Alleles. *Biochem. Biophys. Res. Commun.* 2005, 338, 299–305. [CrossRef] [PubMed]

34. Amirimani, B.; Ning, B.; Deitz, A.C.; Weber, B.L.; Kadlubar, F.F.; Rebbeck, T.R. Increased Transcriptional Activity of the CYP3A4*1B Promoter Variant. *Environ. Mol. Mutagen.* 2003, 42, 299–305. [CrossRef] [PubMed]

35. Gebeyehu, E.; Engidawork, E.; Bijnsdorp, A.; Aminy, A.; Diczfalusy, U.; Aklillu, E. Sex and CYP3A5 Genotype Influence Total CYP3A Activity: High CYP3A Activity and a Unique Distribution of CYP3A5 Variant Alleles in Ethiopians. *Pharm. J.* 2011, 11, 130–137. [CrossRef]

36. Mutagonda, R.F.; Kamuhabwa, A.A.R.; Minzi, O.M.S.; Massawe, S.N.; Asghar, M.; Homann, M.V.; Färnert, A.; Aklillu, E. Effect of Pharmacogenetics on Plasma Lumefantrine Pharmacokinetics and Malaria Treatment Outcome in Pregnant Women. *Malar. J.* 2017, 16, 267. [CrossRef] [PubMed]

37. Mnkugwe, R.H.; Minzi, O.; Kinung’hi, S.; Kamuhabwa, A.; Aklillu, E. Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes among Infected School-Aged Children in Tanzania. *Front. Pharmacol.* 2021, 12, 712084. [CrossRef] [PubMed]

38. De Iudicibus, S.; Castronovo, G.; Gigante, A.; Stocco, G.; Decorti, G.; Di Lenarda, R.; Bartoli, F. Role of MDRI Gene Polymorphisms in Gingival Overgrowth Induced by Cyclosporine in Transplant Patients. *J. Periodontal. Res.* 2008, 43, 665–672. [CrossRef]

39. Fung, K.L.; Gottesman, M.M. A Synonymous Polymorphism in a Common MDRI (ABCB1) Haplotype Shapes Protein Function. *Biochim. Biophys. Acta 2009*, 1794, 860–871. [CrossRef]

40. Ichihara, S.; Yamada, Y.; Kato, K.; Hibino, T.; Yokoi, K.; Matsuo, H.; Kojima, T.; Watanabe, S.; Metoki, N.; Yoshida, H.; et al. Association of a Polymorphism of ABCB1 with Obesity in Japanese Individuals. *Genomics 2008*, 91, 512–516. [CrossRef]